In plain language
In a small randomized trial of 32 thoracic endovascular aortic repair (TEVAR) patients, 3D/3D image fusion gave more accurate guidance and about half the dose area product and contrast volume of 2D/3D fusion. Staff dose was not measured, though lower dose-area product (DAP) usually means less scatter.
At a glance
- Type of study
- Original research, Randomized trial
- Who was studied
- Patients
- Size
- n = 32 patients
- Summary based on
- the abstract
What it found
3D/3D image fusion roughly halved dose area product compared with 2D/3D fusion during TEVAR.
Key figures: 50.5 ± 30.1 Gy cm2 vs 99.5 ± 79.1 Gy cm2; p = 0.03
3D/3D fusion positioned the aortic mask more accurately at the proximal landing zone.
Key figures: 1.7 ± 3.3 mm vs 6.1 ± 6.1 mm; p = 0.03
Contrast volume was lower with 3D/3D fusion.
Key figures: 50.6 ± 22.9 ml vs 98.4 ± 47.9 ml; p = 0.002
Limits to keep in mind
Small single-center randomized trial (32 patients) with unequal groups; only patient DAP was reported, with no direct staff dosimetry.
Related research summaries
- Fluoroscopy-minimization strategy for catheter ablation of Supraventricular Tachycardia by wOmen OPerators: the STOOP Multicentre Registry (2026, Prospective cohort study)
- Two Central Nervous System Tumors in One Catheter Lab: Time to Rethink Radiation Protection (2026, Retrospective cohort study)
- Radiation Awareness for EVAR in Hybrid Operating Room: An Instant Operator Risk Chart (2021, Dosimetry measurement study)
- Utilization of a Radiation Safety Time-Out Reduces Radiation Exposure During Electrophysiology Procedures (2019, Prospective cohort study)
- Completely nonfluoroscopic catheter ablation of left atrial arrhythmias and ventricular tachycardia (2018, Case report or series)
How this summary was made
ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.
Prepared November 3, 2026.